NCT00150254 - 12 Week Evaluation of the Safety and Efficacy of 4 Dosing Strategies of CP-526,555 and Placebo for Smoking Cessation. | Biotech Hunter

Enrollment

625

Participants

Timeline

Start Date

September 30, 2001

Study Completion Date

October 31, 2002

Conditions

Smoking Cessation

Interventions

DRUG

CP-526,555 (varenicline)

Trial Locations (13)

Pfizer Investigational Site, Los Angeles

Pfizer Investigational Site, San Bernardino

Pfizer Investigational Site, Upland

Pfizer Investigational Site, West Covina

Pfizer Investigational Site, Farmington

Pfizer Investigational Site, Jackson

Pfizer Investigational Site, Lexington

Pfizer Investigational Site, New Orleans

Pfizer Investigational Site, Jackson

Pfizer Investigational Site, Omaha

Pfizer Investigational Site, Cincinnati

Pfizer Investigational Site, Portland

Pfizer Investigational Site, Houston